SpaceX Gets All the Attention, but These 3 Under-the-Radar Defense Stocks Have Stronger Fundamentals

The article argues SpaceX stock is expensive and unprofitable, citing $8.7B in net losses and -$19.8B negative free cash flow (FCF). By contrast, it highlights Lockheed Martin with $4.8B in annual profit and $5.7B FCF (priced at ~21x FCF; 2.7% dividend yield) and Huntington Ingalls with $792M positive FCF (14x FCF; 1.9% yield), while positioning Leidos as the cheapest at ~7.2x FCF (1.6% dividend) and ~0.8x annual sales. Overall, the piece is a valuation-based bearish take on SpaceX versus more cash-generative, lower-multiple defense names.

Analysis

This reads less like a SpaceX call and more like a capital-allocation argument: the market is paying up for optionality while ignoring the fact that public defense primes can compound through cash returns today. That favors LMT first because it already monetizes space-adjacent work with real margins, and HII as a slower, lower-multiple way to own defense spend without needing a technology breakthrough. LDOS is the most “value” case, but it is also the most execution-sensitive, so the multiple can stay cheap longer if budget growth or contract awards slip.

The second-order effect is that a strong SpaceX narrative can actually be a near-term overhang for public space-adjacent names if investors frame them as legacy. I think that is overdone for LMT: its space business is not the comp, the comp is the cash yield versus a private asset with no observable FCF. For HII, the issue is different—if defense spending shifts toward drones, cyber, and space, the market may keep discounting shipbuilding. LDOS benefits most if the market re-rates “defense tech” as the cleaner way to own software-heavy government IT, but that rerating is usually catalyzed by backlog growth, not by valuation arguments alone.

Risk-wise, the main reversal is a credible private-market mark-up of SpaceX or a fast-moving strategic event around Starship/Starlink commercialization. That would extend the time horizon of the story premium and keep public comps from closing the valuation gap for 6-18 months. Near term, the trade is mostly about mean reversion in sentiment, not fundamentals; if LMT/HII/LDOS start to outperform on no new operational news, it signals investors are rotating toward yield and visible FCF rather than narrative growth.

Key Decisions for Investors

• Overweight LMT on weakness for a 3-6 month horizon; use the 2.7% yield and FCF yield as downside support, with the thesis falsified if free cash flow degrades or margin guidance steps down.
• Initiate a smaller long HII position as a valuation/quality laggard trade over 6-12 months; risk/reward improves only if defense appropriations stay favorable and mission technologies keeps compounding, while shipbuilding backlog is the key watch item.
• Avoid chasing SPCX-style narrative exposure in public markets; if an investable SpaceX proxy appears through a financing or IPO, expect public-prime multiples to face pressure and reassess the LMT/HII long thesis.
• Use LDOS only as a patient value position, not a momentum trade; buy on contract or guidance-driven drawdowns, and exit if revenue growth stays sub-6% for two quarters while the multiple refuses to expand.
• Relative-value idea: long LMT / underweight weaker-quality defense tech names if the market rotates toward cash return over story stock exposure; trim if defense budget headlines or SpaceX commercialization developments re-open the growth premium.